Viral hepatitis in solid organ transplantation

American Journal of Transplantation

Volumn 13, Issue SUPPL.4, 2013, Pages 147-168

  Levitsky, J ^a   Doucette, K ^b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b UNIVERSITY OF ALBERTA   (Canada)

Author keywords

acyclovir; posttransplant infection; shingles; valacyclovir; varicella infections; viral infection

Indexed keywords

ADEFOVIR; EMTRICITABINE; ENTECAVIR; HEPATITIS B ANTIBODY; HEPATITIS B VACCINE; LAMIVUDINE; NUCLEOSIDE ANALOG; PEGINTERFERON ALPHA; PEGINTERFERON BETA1A; TENOFOVIR;

ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; ARTICLE; DELTA AGENT HEPATITIS; DRUG EFFICACY; DRUG INDICATION; GRAFT RECIPIENT; HEPATITIS A VIRUS; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS DELTA VIRUS; HUMAN; INFECTION CONTROL; INFECTION PREVENTION; INFECTION RISK; LIVER TRANSPLANTATION; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; RECURRENT DISEASE; VIRUS HEPATITIS;

ANTIVIRAL AGENTS; HEPATITIS, VIRAL, HUMAN; HUMANS; ORGAN TRANSPLANTATION; RISK FACTORS;

EID: 84874873249     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.12108     Document Type: Article

References (335)

1. Franco E, Giambi C, Ialacci R, Coppola RC, Zanetti AR,. Risk groups for hepatitis A virus infection. Vaccine 2003; 21: 2224-2233.
2. Richardson LC, Evatt BL,. Risk of hepatitis A virus infection in persons with hemophilia receiving plasma-derived products. Transfusion Med Rev 2000; 14: 64-73.
3. Jacobsen KH, Wiersma ST,. Hepatitis A virus seroprevalence by age and world region, 1990 and 2005. Vaccine; 28: 6653-6657.
4. Centers for Disease Control and Prevention (CDC). Prevention of hepatitis A through active or passive immunization: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1999; 48: 1-37.
5. Cuthbert JA,. Hepatitis A: Old and new. Clin Microbiol Rev 2001; 14: 38-58.
6. Debray D, Cullufi P, Devictor D, Fabre M, Bernard O,. Liver failure in children with hepatitis A. Hepatology 1997; 26: 1018-1022.
7. Schiodt FV, Atillasoy E, Shakil AO, et al. Etiology and outcome for 295 patients with acute liver failure in the United States. Liver Transpl Surg 1999; 5: 29-34.
8. Fagan E, Yousef G, Brahm J, et al. Persistence of hepatitis A virus in fulminant hepatitis and after liver transplantation. J Med Virol 1990; 30: 131-136.
9. Gane E, Sallie R, Saleh M, Portmann B, Williams R,. Clinical recurrence of hepatitis A following liver transplantation for acute liver failure. J Med Virol 1995; 45: 35-39.
10. Lee WM,. Hepatitis B virus infection. N Engl J Med 1997; 337: 1733-1745.
11. Poland GA, Jacobson RM,. Clinical practice: Prevention of hepatitis B with the hepatitis B vaccine. N Engl J Med 2004; 351: 2832-2838.
12. Ueda Y, Marusawa H, Egawa H, et al. De novo activation of HBV with escape mutations from hepatitis B surface antibody after living donor liver transplantation. Antivir Ther 2011; 16: 479-487.
13. Cohen C, Evans AA, London WT, Block J, Conti M, Block T,. Underestimation of chronic hepatitis B virus infection in the United States of America. J Viral Hepat 2008; 15: 12-13.
14. Brind A, Jiang J, Samuel D, et al. Evidence for selection of hepatitis B mutants after liver transplantation through peripheral blood mononuclear cell infection. J Hepatol 1997; 26: 228-235.
15. Feray C, Zignego AL, Samuel D, et al. Persistent hepatitis B virus infection of mononuclear blood cells without concomitant liver infection. The liver transplantation model. Transplantation 1990; 49: 1155-1158.
16. Mazet-Wagner AA, Baclet MC, Loustaud-Ratti V, Denis F, Alain S,. Real-time PCR quantitation of hepatitis B virus total DNA and covalently closed circular DNA in peripheral blood mononuclear cells from hepatitis B virus-infected patients. J Virol Methods 2006; 138: 70-79.
17. Todo S, Demetris AJ, Van Thiel D, Teperman L, Fung JJ, Starzl TE,. Orthotopic liver transplantation for patients with hepatitis B virus-related liver disease. Hepatology 1991; 13: 619-626.
18. O'Grady JG, Smith HM, Davies SE, et al. Hepatitis B virus reinfection after orthotopic liver transplantation. Serological and clinical implications. J Hepatol 1992; 14: 104-111.
19. Starzl TE, Demetris AJ, Van Thiel D,. Liver transplantation (2). N Engl J Med 1989; 321: 1092-1099.
20. Vierling JM, Teperman LW,. Introduction to hepatitis B transplantation. Semin Liver Dis 2000; 20 (Suppl 1): 1-2.
21. Buti M, Mas A, Prieto M, et al. A randomized study comparing lamivudine monotherapy after a short course of hepatitis B immune globulin (HBIg) and lamivudine with long-term lamivudine plus HBIg in the prevention of hepatitis B virus recurrence after liver transplantation. J Hepatol 2003; 38: 811-817.
22. Coffin CS, Terrault NA,. Management of hepatitis B in liver transplant recipients. Journal of viral hepatitis 2007; 14 (Suppl 1): 37-44.
23. Kapoor D, Guptan RC, Wakil SM, et al. Beneficial effects of lamivudine in hepatitis B virus-related decompensated cirrhosis. J Hepatol 2000; 33: 308-312.
24. Perrillo RP, Wright T, Rakela J, et al. A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B. Hepatology 2001; 33: 424-432.
25. Villeneuve JP, Condreay LD, Willems B, et al. Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B. Hepatology 2000; 31: 207-210.
26. Yao FY, Terrault NA, Freise C, Maslow L, Bass NM,. Lamivudine treatment is beneficial in patients with severely decompensated cirrhosis and actively replicating hepatitis B infection awaiting liver transplantation: A comparative study using a matched, untreated cohort. Hepatology 2001; 34: 411-416.
27. Roche B, Roque-Afonso AM, Sebagh M, et al. Escape hepatitis B virus mutations in recipients of antibody to hepatitis B core antigen-positive liver grafts receiving hepatitis B immunoglobulins. Liver Transpl 2010; 16: 885-894.
28. Allen MI, Deslauriers M, Andrews CW, et al. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group. Hepatology 1998; 27: 1670-1677.
29. Cooreman MP, Leroux-Roels G, Paulij WP,. Vaccine- and hepatitis B immune globulin-induced escape mutations of hepatitis B virus surface antigen. J Biomed Sci 2001; 8: 237-247.
30. Stuyver LJ, Locarnini SA, Lok A, et al. Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region. Hepatology 2001; 33: 751-757.
31. Marzano A, Gaia S, Ghisetti V, et al. Viral load at the time of liver transplantation and risk of hepatitis B virus recurrence. Liver Transpl 2005; 11: 402-409.
32. Marzano A, Lampertico P, Mazzaferro V, et al. Prophylaxis of hepatitis B virus recurrence after liver transplantation in carriers of lamivudine-resistant mutants. Liver Transpl 2005; 11: 532-538.
33. Samuel D, Muller R, Alexander G, et al. Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med 1993; 329: 1842-1847.
34. Zheng S, Chen Y, Liang T, et al. Prevention of hepatitis B recurrence after liver transplantation using lamivudine or lamivudine combined with hepatitis B Immunoglobulin prophylaxis. Liver Transpl 2006; 12: 253-258.
35. Roche B, Feray C, Gigou M, et al. HBV DNA persistence 10 years after liver transplantation despite successful anti-HBS passive immunoprophylaxis. Hepatology 2003; 38: 86-95.
36. Terrault NA, Zhou S, Combs C, et al. Prophylaxis in liver transplant recipients using a fixed dosing schedule of hepatitis B immunoglobulin. Hepatology 1996; 24: 1327-1333.
37. Tabor E,. Infections by hepatitis B surface antigen gene mutants in Europe and North America. J Med Virol 2006; 78 (Suppl 1): S43-47.
38. Angus PW, Locarnini SA, McCaughan GW, Jones RM, McMillan JS, Bowden DS,. Hepatitis B virus precore mutant infection is associated with severe recurrent disease after liver transplantation. Hepatology 1995; 21: 14-18.
39. Keeffe EB, Dieterich DT, Han SH, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: An update. Clin Gastroenterol Hepatol 2006; 4: 936-962.
40. Lok AS, McMahon BJ,. Chronic hepatitis B. Hepatology 2007; 45: 507-539.
41. Sherman M, Shafran S, Burak K, et al. Management of chronic hepatitis B: Consensus guidelines. Can J Gastroenterol 2007; 21 (Suppl C): 5C-24C.
42. Liaw YF, Sheen IS, Lee CM, et al. Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease. Hepatology 2011; 53: 62-72.
43. Murphy MD, O'Hearn M, Chou S,. Fatal lactic acidosis and acute renal failure after addition of tenofovir to an antiretroviral regimen containing didanosine. Clin Infect Dis 2003; 36: 1082-1085.
44. Lange CM, Bojunga J, Hofmann WP, et al. Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function. Hepatology 2009; 50: 2001-2006.
45. Lok AS, McMahon BJ,. Chronic hepatitis B: Update 2009. Hepatology 2009; 50: 661-662.
46. Tenney DJ, Rose RE, Baldick CJ, et al. Two-year assessment of entecavir resistance in Lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present. Antimicrob Agents Chemother 2007; 51: 902-911.
47. Tan J, Degertekin B, Wong SN, Husain M, Oberhelman K, Lok AS,. Tenofovir monotherapy is effective in hepatitis B patients with antiviral treatment failure to adefovir in the absence of adefovir-resistant mutations. J Hepatol 2008; 48: 391-398.
48. Schiff ER, Lai CL, Hadziyannis S, et al. Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients. Hepatology 2003; 38: 1419-1427.
49. Perrillo R, Hann HW, Mutimer D, et al. Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. Gastroenterology 2004; 126: 81-90.
50. Barcena R, Del Campo S, Moraleda G, et al. Study on the efficacy and safety of adefovir dipivoxil treatment in post-liver transplant patients with hepatitis B virus infection and lamivudine-resistant hepatitis B virus. Transplant Proc 2005; 37: 3960-3962.
51. Neff GW, Nery J, Lau DT, et al. Tenofovir therapy for lamivudine resistance following liver transplantation. Ann Pharmacother 2004; 38: 1999-2004.
52. Neff GW, O'Brien CB, Nery J, et al. Outcomes in liver transplant recipients with hepatitis B virus: Resistance and recurrence patterns from a large transplant center over the last decade. Liver Transpl 2004; 10: 1372-1378.
53. Mailliard ME, Capadano ME, Hrnicek MJ, Gilroy RK, Gulizia JM,. Outcomes of a patient-to-patient outbreak of genotype 3a hepatitis C. Hepatology 2009; 50: 361-368.
54. Daude M, Rostaing L, Saune K, et al. Tenofovir therapy in hepatitis B virus-positive solid-organ transplant recipients. Transplantation 2011; 91: 916-920.
55. Mathew G, Knaus SJ,. Acquired Fanconi's syndrome associated with tenofovir therapy. J Gen Intern Med 2006; 21: C3-5.
56. Jung YK, Yeon JE, Choi JH, et al. Fanconi's syndrome associated with prolonged adefovir dipivoxil therapy in a hepatitis B virus patient. Gut Liver 2010; 4: 389-393.
57. Markowitz JS, Martin P, Conrad AJ, et al. Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin. Hepatology 1998; 28: 585-589.
58. Dumortier J, Chevallier P, Scoazec JY, Berger F, Boillot O,. Combined lamivudine and hepatitis B immunoglobulin for the prevention of hepatitis B recurrence after liver transplantation: Long-term results. Am J Transplant 2003; 3: 999-1002.
59. Han SH, Ofman J, Holt C, et al. An efficacy and cost-effectiveness analysis of combination hepatitis B immune globulin and lamivudine to prevent recurrent hepatitis B after orthotopic liver transplantation compared with hepatitis B immune globulin monotherapy. Liver Transpl 2000; 6: 741-748.
60. Loomba R, Rowley AK, Wesley R, et al. Hepatitis B immunoglobulin and Lamivudine improve hepatitis B-related outcomes after liver transplantation: Meta-analysis. Clin Gastroenterol Hepatol 2008; 6: 696-700.
61. Marzano A, Salizzoni M, Debernardi-Venon W, et al. Prevention of hepatitis B virus recurrence after liver transplantation in cirrhotic patients treated with lamivudine and passive immunoprophylaxis. J Hepatol 2001; 34: 903-910.
62. Steinmuller T, Seehofer D, Rayes N, et al. Increasing applicability of liver transplantation for patients with hepatitis B-related liver disease. Hepatology 2002; 35: 1528-1535.
63. Gane EJ, Angus PW, Strasser S, et al. Lamivudine plus low-dose hepatitis B immunoglobulin to prevent recurrent hepatitis B following liver transplantation. Gastroenterology 2007; 132: 931-937.
64. Anselmo DM, Ghobrial RM, Jung LC, et al. New era of liver transplantation for hepatitis B: A 17-year single-center experience. Ann Surg 2002; 235: 611-619; discussion 619-620.
65. Yao FY, Osorio RW, Roberts JP, et al. Intramuscular hepatitis B immune globulin combined with lamivudine for prophylaxis against hepatitis B recurrence after liver transplantation. Liver Transpl Surg 1999; 5: 491-496.
66. Yan ML, Yan LN, Li B, et al. Intramuscular hepatitis B immune globulin combined with lamivudine in prevention of hepatitis B recurrence after liver transplantation. Hepatobiliary Pancreat Dis Int 2006; 5: 360-363.
67. Angus PW, McCaughan GW, Gane EJ, Crawford DH, Harley H,. Combination low-dose hepatitis B immune globulin and lamivudine therapy provides effective prophylaxis against posttransplantation hepatitis B. Liver Transpl 2000; 6: 429-433.
68. Naoumov NV, Lopes AR, Burra P, et al. Randomized trial of lamivudine versus hepatitis B immunoglobulin for long-term prophylaxis of hepatitis B recurrence after liver transplantation. J Hepatol 2001; 34: 888-894.
69. Lo CM, Liu CL, Lau GK, Chan SC, Ng IO, Fan ST,. Liver transplantation for chronic hepatitis B with lamivudine-resistant YMDD mutant using add-on adefovir dipivoxil plus lamivudine. Liver Transpl 2005; 11: 807-813.
70. Todd, Stravitz R, Shiffman ML, Kimmel M, et al. Substitution of tenofovir/emtricitabine for Hepatitis B immune globulin prevents recurrence of Hepatitis B after liver transplantation. Liver Int 2012.
71. Karlas T, Hartmann J, Weimann A, et al. Prevention of lamivudine-resistant hepatitis B recurrence after liver transplantation with entecavir plus tenofovir combination therapy and perioperative hepatitis B immunoglobulin only. Transpl Infect Dis 2011; 13: 299-302.
72. Jimenez-Perez M, Saez-Gomez AB, Mongil Poce L, Lozano-Rey JM, de la Cruz-Lombardo J, Rodrigo-Lopez JM,. Efficacy and safety of entecavir and/or tenofovir for prophylaxis and treatment of hepatitis B recurrence post-liver transplant. Transplant Proc 2010; 42: 3167-3168.
73. Ueda Y, Marusawa H, Kaido T, et al. Efficacy and safety of prophylaxis with entecavir and hepatitis B immunoglobulin in preventing hepatitis B recurrence after living-donor liver transplantation. Hepatol Res 2012.
74. Fung J, Cheung C, Chan SC, et al. Entecavir monotherapy is effective in suppressing hepatitis B virus after liver transplantation. Gastroenterology 2011; 141: 1212-1219.
75. Xi ZF, Xia Q, Zhang JJ, et al. The role of entecavir in preventing hepatitis B recurrence after liver transplantation. J Dig Dis 2009; 10: 321-327.
76. Lenci I, Tisone G, Di Paolo D, et al. Safety of complete and sustained prophylaxis withdrawal in patients liver-transplanted for HBV-related cirrhosis at low risk of HBV recurrence. J Hepatol 2011; 55: 587-593.
77. Angelico M, Di Paolo D, Trinito MO, et al. Failure of a reinforced triple course of hepatitis B vaccination in patients transplanted for HBV-related cirrhosis. Hepatology 2002; 35: 176-181.
78. Bienzle U, Gunther M, Neuhaus R, Neuhaus P,. Successful hepatitis B vaccination in patients who underwent transplantation for hepatitis B virus-related cirrhosis: Preliminary results. Liver Transpl 2002; 8: 562-564.
79. Lo CM, Liu CL, Chan SC, Lau GK, Fan ST,. Failure of hepatitis B vaccination in patients receiving lamivudine prophylaxis after liver transplantation for chronic hepatitis B. J Hepatol 2005; 43: 283-287.
80. Sanchez-Fueyo A, Rimola A, Grande L, et al. Hepatitis B immunoglobulin discontinuation followed by hepatitis B virus vaccination: A new strategy in the prophylaxis of hepatitis B virus recurrence after liver transplantation. Hepatology 2000; 31: 496-501.
81. Nery JR, Nery-Avila C, Reddy KR, et al. Use of liver grafts from donors positive for antihepatitis B-core antibody (anti-HBc) in the era of prophylaxis with hepatitis-B immunoglobulin and lamivudine. Transplantation 2003; 75: 1179-1186.
82. Cholongitas E, Papatheodoridis GV, Burroughs AK,. Liver grafts from anti-hepatitis B core positive donors: A systematic review. J Hepatol 2010; 52: 272-279.
83. Fabrega E, Garcia-Suarez C, Guerra A, et al. Liver transplantation with allografts from hepatitis B core antibody-positive donors: A new approach. Liver Transpl 2003; 9: 916-920.
84. Yu AS, Vierling JM, Colquhoun SD, et al. Transmission of hepatitis B infection from hepatitis B core antibody-positive liver allografts is prevented by lamivudine therapy. Liver Transpl 2001; 7: 513-517.
85. Dodson SF, Bonham CA, Geller DA, Cacciarelli TV, Rakela J, Fung JJ,. Prevention of de novo hepatitis B infection in recipients of hepatic allografts from anti-HBc positive donors. Transplantation 1999; 68: 1058-1061.
86. Prakoso E, Strasser SI, Koorey DJ, Verran D, McCaughan GW,. Long-term lamivudine monotherapy prevents development of hepatitis B virus infection in hepatitis B surface-antigen negative liver transplant recipients from hepatitis B core-antibody-positive donors. Clin Transplant 2006; 20: 369-373.
87. Saab S, Waterman B, Chi AC, Tong MJ,. Comparison of different immunoprophylaxis regimens after liver transplantation with hepatitis B core antibody-positive donors: A systematic review. Liver Transpl 2010; 16: 300-307.
88. Roque-Afonso AM, Feray C, Samuel D, et al. Antibodies to hepatitis B surface antigen prevent viral reactivation in recipients of liver grafts from anti-HBC positive donors. Gut 2002; 50: 95-99.
89. Chang MS, Olsen SK, Pichardo EM, et al. Prevention of de novo hepatitis B with adefovir dipivoxil (ADV) in recipients of liver grafts from hepatitis B core antibody positive (HBcAb+) donors. Liver Transpl 2012.
90. Arslan M, Wiesner RH, Sievers C, Egan K, Zein NN,. Double-dose accelerated hepatitis B vaccine in patients with end-stage liver disease. Liver Transpl 2001; 7: 314-320.
91. Chalasani N, Smallwood G, Halcomb J, Fried MW, Boyer TD,. Is vaccination against hepatitis B infection indicated in patients waiting for or after orthotopic liver transplantation? Liver Transpl Surg 1998; 4: 128-132.
92. Dominguez M, Barcena R, Garcia M, Lopez-Sanroman A, Nuno J,. Vaccination against hepatitis B virus in cirrhotic patients on liver transplant waiting list. Liver Transpl 2000; 6: 440-442.
93. Horlander JC, Boyle N, Manam R, et al. Vaccination against hepatitis B in patients with chronic liver disease awaiting liver transplantation. Am J Med Sci 1999; 318: 304-307.
94. Loinaz C, de Juanes JR, Gonzalez EM, et al. Hepatitis B vaccination results in 140 liver transplant recipients. Hepatogastroenterology 1997; 44: 235-238.
95. Van Thiel DH, el-Ashmawy L, Love K, Gavaler JS, Starzl TE,. Response to hepatitis B vaccination by liver transplant candidates. Dig Dis Sci 1992; 37: 1245-1249.
96. Villeneuve E, Vincelette J, Villeneuve JP,. Ineffectiveness of hepatitis B vaccination in cirrhotic patients waiting for liver transplantation. Can J Gastroenterol 2000; 14 (Suppl B): 59B-62B.
97. Burdick RA, Bragg-Gresham JL, Woods JD, et al. Patterns of hepatitis B prevalence and seroconversion in hemodialysis units from three continents: The DOPPS. Kidney Int 2003; 63: 2222-2229.
98. Johnson DW, Dent H, Yao Q, et al. Frequencies of hepatitis B and C infections among haemodialysis and peritoneal dialysis patients in Asia-Pacific countries: Analysis of registry data. Nephrol Dial Transplant 2009; 24: 1598-1603.
99. Thompson ND, Perz JF, Moorman AC, Holmberg SD,. Nonhospital health care-associated hepatitis B and C virus transmission: United States, 1998-2008. Ann Inter Med 2009; 150: 33-39.
100. Lanini S, Puro V, Lauria FN, Fusco FM, Nisii C, Ippolito G,. Patient to patient transmission of hepatitis B virus: A systematic review of reports on outbreaks between 1992 and 2007. BMC Med 2009; 7: 15.
101. Hayney MS, Welter DL, Reynolds AM, Francois M, Love RB,. High-dose hepatitis B vaccine in patients waiting for lung transplantation. Pharmacotherapy 2003; 23: 555-560.
102. Marcellin P, Giostra E, Martinot-Peignoux M, et al. Redevelopment of hepatitis B surface antigen after renal transplantation. Gastroenterology 1991; 100 (Pt 1): 1432-1434.
103. Dusheiko G, Song E, Bowyer S, et al. Natural history of hepatitis B virus infection in renal transplant recipients-a fifteen-year follow-up. Hepatology 1983; 3: 330-336.
104. Degos F, Lugassy C, Degott C, et al. Hepatitis B virus and hepatitis B-related viral infection in renal transplant recipients. A prospective study of 90 patients. Gastroenterology 1988; 94: 151-156.
105. Lezaic V, Stosovic M, Marinkovic J, Rangelov V, Djukanovic L,. Hepatitis B and hepatitis C virus infection and outcome of hemodialysis and kidney transplant patients. Renal failure 2008; 30: 81-87.
106. Mathurin P, Mouquet C, Poynard T, et al. Impact of hepatitis B and C virus on kidney transplantation outcome. Hepatology 1999; 29: 257-263.
107. Kletzmayr J, Watschinger B,. Chronic hepatitis B virus infection in renal transplant recipients. Semin Nephrol 2002; 22: 375-389.
108. Wedemeyer H, Pethig K, Wagner D, et al. Long-term outcome of chronic hepatitis B in heart transplant recipients. Transplantation 1998; 66: 1347-1353.
109. Ko WJ, Chou NK, Hsu RB, et al. Hepatitis B virus infection in heart transplant recipients in a hepatitis B endemic area. J Heart Lung Transplant 2001; 20: 865-875.
110. Potthoff A, Tillmann HL, Bara C, et al. Improved outcome of chronic hepatitis B after heart transplantation by long-term antiviral therapy. J Viral Hepat 2006; 13: 734-741.
111. Ahn HJ, Kim MS, Kim YS, et al. Clinical outcome of renal transplantation in patients with positive pre-transplant hepatitis B surface antigen. J Med Virol 2007; 79: 1655-1663.
112. Reddy PN, Sampaio MS, Kuo HT, Martin P, Bunnapradist S,. Impact of pre-existing hepatitis B infection on the outcomes of kidney transplant recipients in the United States. Clin J Am Soc Nephrol; 6: 1481-1487.
113. Yap DY, Tang CS, Yung S, Choy BY, Yuen MF, Chan TM,. Long-term outcome of renal transplant recipients with chronic hepatitis B infection-impact of antiviral treatments. Transplantation; 90: 325-330.
114. Park SK, Yang WS, Lee YS, et al. Outcome of renal transplantation in hepatitis B surface antigen-positive patients after introduction of lamivudine. Nephrol Dial Transplant 2001; 16: 2222-2228.
115. Wasley A, Kruszon-Moran D, Kuhnert W, et al. The prevalence of hepatitis B virus infection in the United States in the era of vaccination. J Infect Dis; 202: 192-201.
116. Knoll A, Pietrzyk M, Loss M, Goetz WA, Jilg W,. Solid-organ transplantation in HBsAg-negative patients with antibodies to HBV core antigen: Low risk of HBV reactivation. Transplantation 2005; 79: 1631-1633.
117. Blanpain C, Knoop C, Delforge ML, et al. Reactivation of hepatitis B after transplantation in patients with pre-existing anti-hepatitis B surface antigen antibodies: Report on three cases and review of the literature. Transplantation 1998; 66: 883-886.
118. European Association For The Study Of The L. EASL Clinical Practice Guidelines: Management of chronic hepatitis B virus infection. J Hepatol.
119. Bruix J, Sherman M,. Management of hepatocellular carcinoma: An update. Hepatology 2011; 53: 1020-1022.
120. Keating GM, Noble S,. Recombinant hepatitis B vaccine (Engerix-B): A review of its immunogenicity and protective efficacy against hepatitis B. Drugs 2003; 63: 1021-1051.
121. DaRoza G, Loewen A, Djurdjev O, et al. Stage of chronic kidney disease predicts seroconversion after hepatitis B immunization: Earlier is better. Am J Kidney Dis 2003; 42: 1184-1192.
122. Foster WQ, Murphy A, Vega DJ, Smith AL, Hott BJ, Book WM,. Hepatitis B vaccination in heart transplant candidates. J Heart Lung Transplant 2006; 25: 106-109.
123. Lefebure AF, Verpooten GA, Couttenye MM, De Broe ME,. Immunogenicity of a recombinant DNA hepatitis B vaccine in renal transplant patients. Vaccine 1993; 11: 397-399.
124. Jacobson IM, Jaffers G, Dienstag JL, et al. Immunogenicity of hepatitis B vaccine in renal transplant recipients. Transplantation 1985; 39: 393-395.
125. Yap DY, Tang CS, Yung S, Choy BY, Yuen MF, Chan TM,. Long-term outcome of renal transplant recipients with chronic hepatitis B infection-impact of antiviral treatments. Transplantation 2010; 90: 325-330.
126. Tse KC, Yap DY, Tang CS, Yung S, Chan TM,. Response to adefovir or entecavir in renal allograft recipients with hepatitic flare due to lamivudine-resistant hepatitis B. Clin Transplant; 24: 207-212.
127. Chung RT, Feng S, Delmonico FL,. Approach to the management of allograft recipients following the detection of hepatitis B virus in the prospective organ donor. Am J Transplant 2001; 1: 185-191.
128. Chan PC, Lok AS, Cheng IK, Chan MK,. The impact of donor and recipient hepatitis B surface antigen status on liver disease and survival in renal transplant recipients. Transplantation 1992; 53: 128-131.
129. Jiang H, Wu J, Zhang X, et al. Kidney transplantation from hepatitis B surface antigen positive donors into hepatitis B surface antibody positive recipients: A prospective nonrandomized controlled study from a single center. Am J Transplant 2009; 9: 1853-1858.
130. Wei HK, Loong CC, King KL, Wu CW, Lui WY,. HBsAg(+) donor as a kidney transplantation deceased donor. Transplant Proc 2008; 40: 2097-2099.
131. Fabrizio F, Bunnapradist S, Martin P,. Transplanting kidneys from donors with prior hepatitis B infection: One response to the organ shortage. J Nephrol 2002; 15: 605-613.
132. Madayag RM, Johnson LB, Bartlett ST, et al. Use of renal allografts from donors positive for hepatitis B core antibody confers minimal risk for subsequent development of clinical hepatitis B virus disease. Transplantation 1997; 64: 1781-1786.
133. Dhillon GS, Levitt J, Mallidi H, et al. Impact of hepatitis B core antibody positive donors in lung and heart-lung transplantation: An analysis of the United Network For Organ Sharing Database. Transplantation 2009; 88: 842-846.
134. Salvadori M, Rosso G, Carta P, Larti A, di Maria L, Bertoni E,. Donors positive for hepatitis B core antibodies in nonliver transplantations. Transplant Proc 2011; 43: 277-279.
135. Robertson B, Myers G, Howard C, et al. Classification, nomenclature, and database development for hepatitis C virus (HCV) and related viruses: Proposals for standardization. International Committee on Virus Taxonomy. Arch Virol 1998; 143: 2493-2503.
136. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 2003; 348: 800-807.
137. Lauer GM, Walker BD,. Hepatitis C virus infection. N Engl J Med 2001; 345: 41-52.
138. Davis GL, Albright JE, Cook SF, Rosenberg DM,. Projecting future complications of chronic hepatitis C in the United States. Liver Transpl 2003; 9: 331-338.
139. Berenguer M,. Natural history of recurrent hepatitis C. Liver Transpl 2002; 8 (Suppl 1): S14-18.
140. Berenguer M, Prieto M, Rayon JM, et al. Natural history of clinically compensated hepatitis C virus-related graft cirrhosis after liver transplantation. Hepatology 2000; 32 (Pt 1): 852-858.
141. Forman LM, Lewis JD, Berlin JA, Feldman HI, Lucey MR,. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 2002; 122: 889-896.
142. Firpi RJ, Abdelmalek MF, Soldevila-Pico C, et al. One-year protocol liver biopsy can stratify fibrosis progression in liver transplant recipients with recurrent hepatitis C infection. Liver Transpl 2004; 10: 1240-1247.
143. Saab S, Niho H, Comulada S, et al. Mortality predictors in liver transplant recipients with recurrent hepatitis C cirrhosis. Liver Int 2005; 25: 940-945.
144. Brown RS,. Hepatitis C and liver transplantation. Nature 2005; 436: 973-978.
145. Watt KD, Lyden ER, McCashland TM,. Poor survival after liver retransplantation: Is hepatitis C to blame? Liver Transpl 2003; 9: 1019-1024.
146. Doyle HR, Morelli F, McMichael J, et al. Hepatic retransplantation-An analysis of risk factors associated with outcome. Transplantation 1996; 61: 1499-1505.
147. Ghobrial RM, Gornbein J, Steadman R, et al. Pretransplant model to predict posttransplant survival in liver transplant patients. Ann Surg 2002; 236: 315-322; discussion 322-313.
148. Markmann JF, Markowitz JS, Yersiz H, et al. Long-term survival after retransplantation of the liver. Ann Surg 1997; 226: 408-418; discussion 418-420.
149. McCashland T, Watt K, Lyden E, et al. Retransplantation for hepatitis C: Results of a U.S. multicenter retransplant study. Liver Transpl 2007; 13: 1246-1253.
150. Neff GW, O'Brien CB, Nery J, et al. Factors that identify survival after liver retransplantation for allograft failure caused by recurrent hepatitis C infection. Liver Transpl 2004; 10: 1497-1503.
151. Pelletier SJ, Schaubel DE, Punch JD, Wolfe RA, Port FK, Merion RM,. Hepatitis C is a risk factor for death after liver retransplantation. Liver Transpl 2005; 11: 434-440.
152. Rosen HR, Prieto M, Casanovas-Taltavull T, et al. Validation and refinement of survival models for liver retransplantation. Hepatology 2003; 38: 460-469.
153. Watt KD, Menke T, Lyden E, McCashland TM,. Mortality while awaiting liver retransplantation: Predictability of MELD scores. Transplant Proc 2005; 37: 2172-2173.
154. Yao FY, Saab S, Bass NM, et al. Prediction of survival after liver retransplantation for late graft failure based on preoperative prognostic scores. Hepatology 2004; 39: 230-238.
155. Charlton M, Ruppert K, Belle SH, et al. Long-term results and modeling to predict outcomes in recipients with HCV infection: Results of the NIDDK liver transplantation database. Liver Transpl 2004; 10: 1120-1130.
156. De Ruvo N, Cucchetti A, Lauro A, et al. Preliminary results of a "prope" tolerogenic regimen with thymoglobulin pretreatment and hepatitis C virus recurrence in liver transplantation. Transplantation 2005; 80: 8-12.
157. Eason JD, Nair S, Cohen AJ, Blazek JL, Loss GE, Jr., Steroid-free liver transplantation using rabbit antithymocyte globulin and early tacrolimus monotherapy. Transplantation 2003; 75: 1396-1399.
158. Nair S, Loss GE, Cohen AJ, Eason JD,. Induction with rabbit antithymocyte globulin versus induction with corticosteroids in liver transplantation: Impact on recurrent hepatitis C virus infection. Transplantation 2006; 81: 620-622.
159. Klintmalm G, Fasola CG, Jennings L, et al. Hepatitis C-3 study: Does immunosuppression affect the progression of fibrosis of HCV recurrence after liver transplantation. Hepatology 2007; 46: Abstract 7.
160. Berenguer M, Prieto M, Cordoba J, et al. Early development of chronic active hepatitis in recurrent hepatitis C virus infection after liver transplantation: Association with treatment of rejection. J Hepatol 1998; 28: 756-763.
161. Charlton M, Seaberg E,. Impact of immunosuppression and acute rejection on recurrence of hepatitis C: Results of the National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database. Liver Transpl Surg 1999; 5 (Suppl 1): S107-114.
162. Charlton M, Seaberg E, Wiesner R, et al. Predictors of patient and graft survival following liver transplantation for hepatitis C. Hepatology 1998; 28: 823-830.
163. Nelson DR, Soldevila-Pico C, Reed A, et al. Anti-interleukin-2 receptor therapy in combination with mycophenolate mofetil is associated with more severe hepatitis C recurrence after liver transplantation. Liver Transpl 2001; 7: 1064-1070.
164. Neumann UP, Berg T, Bahra M, et al. Fibrosis progression after liver transplantation in patients with recurrent hepatitis C. J Hepatol 2004; 41: 830-836.
165. Rosen HR, Shackleton CR, Higa L, et al. Use of OKT3 is associated with early and severe recurrence of hepatitis C after liver transplantation. Am J Gastroenterol 1997; 92: 1453-1457.
166. Sheiner PA, Schwartz ME, Mor E, et al. Severe or multiple rejection episodes are associated with early recurrence of hepatitis C after orthotopic liver transplantation. Hepatology 1995; 21: 30-34.
167. Watt KD, Lyden ER, Gulizia JM, McCashland TM,. Recurrent hepatitis C posttransplant: Early preservation injury may predict poor outcome. Liver Transpl 2006; 12: 134-139.
168. Rosen HR, Chou S, Corless CL, et al. Cytomegalovirus viremia: Risk factor for allograft cirrhosis after liver transplantation for hepatitis C. Transplantation 1997; 64: 721-726.
169. Charlton MR, Thompson A, Veldt BJ, et al. Interleukin-28B polymorphisms are associated with histological recurrence and treatment response following liver transplantation in patients with hepatitis C virus infection. Hepatology 2011; 53: 317-324.
170. Coto-Llerena M, Perez-Del-Pulgar S, Crespo G, et al. Donor and recipient IL28B polymorphisms in HCV-infected patients undergoing antiviral therapy before and after liver transplantation. Am J Transplant 2011; 11: 1051-1057.
171. Eurich D, Boas-Knoop S, Bahra M, et al. Role of IL28B polymorphism in the development of hepatitis C virus-induced hepatocellular carcinoma, graft fibrosis, and posttransplant antiviral therapy. Transplantation 2012; 93: 644-649.
172. Fukuhara T, Taketomi A, Motomura T, et al. Variants in IL28B in liver recipients and donors correlate with response to peg-interferon and ribavirin therapy for recurrent hepatitis C. Gastroenterology 2010; 139: 1577-1585, 1585 e1571-1573.
173. Lange CM, Moradpour D, Doehring A, et al. Impact of donor and recipient IL28B rs12979860 genotypes on hepatitis C virus liver graft reinfection. J Hepatol 2011; 55: 322-327.
174. Brandman D, Pingitore A, Lai JC, et al. Hepatic steatosis at 1 year is an additional predictor of subsequent fibrosis severity in liver transplant recipients with recurrent hepatitis C virus. Liver Transpl 2011; 17: 1380-1386.
175. Bahra M, Neumann UI, Jacob D, et al. MMF and calcineurin taper in recurrent hepatitis C after liver transplantation: Impact on histological course. Am J Transplant 2005; 5: 406-411.
176. Belli LS, Alberti AB, Vangeli M, Airoldi A, Pinzello G,. Tapering off steroids three months after liver transplantation is not detrimental for hepatitis C virus disease recurrence. Liver Transpl 2003; 9: 201-202.
177. Belli LS, Burra P, Poli F, et al. HLA-DRB1 donor-recipient mismatch affects the outcome of hepatitis C disease recurrence after liver transplantation. Gastroenterology 2006; 130: 695-702.
178. Ben-Ari Z, Tambur AR, Pappo O, et al. Platelet-derived growth factor gene polymorphism in recurrent hepatitis C infection after liver transplantation. Transplantation 2006; 81: 392-397.
179. Berenguer M,. Treatment of chronic hepatitis C in hemodialysis patients. Hepatology 2008; 48: 1690-1699.
180. Berenguer M, Aguilera V, Prieto M, et al. Effect of calcineurin inhibitors on survival and histologic disease severity in HCV-infected liver transplant recipients. Liver Transpl 2006; 12: 762-767.
181. Berenguer M, Aguilera V, Prieto M, et al. Significant improvement in the outcome of HCV-infected transplant recipients by avoiding rapid steroid tapering and potent induction immunosuppression. J Hepatol 2006; 44: 717-722.
182. Berenguer M, Ferrell L, Watson J, et al. HCV-related fibrosis progression following liver transplantation: Increase in recent years. J Hepatol 2000; 32: 673-684.
183. Berenguer M, Royuela A, Zamora J,. Immunosuppression with calcineurin inhibitors with respect to the outcome of HCV recurrence after liver transplantation: Results of a meta-analysis. Liver Transpl 2007; 13: 21-29.
184. Brillanti S, Vivarelli M, De Ruvo N, et al. Slowly tapering off steroids protects the graft against hepatitis C recurrence after liver transplantation. Liver Transpl 2002; 8: 884-888.
185. Burak KW, Kremers WK, Batts KP, et al. Impact of cytomegalovirus infection, year of transplantation, and donor age on outcomes after liver transplantation for hepatitis C. Liver Transpl 2002; 8: 362-369.
186. Filipponi F, Callea F, Salizzoni M, et al. Double-blind comparison of hepatitis C histological recurrence Rate in HCV+ Liver transplant recipients given basiliximab + steroids or basiliximab + placebo, in addition to cyclosporine and azathioprine. Transplantation 2004; 78: 1488-1495.
187. Fisher RA, Stone JJ, Wolfe LG, et al. Four-year follow-up of a prospective randomized trial of mycophenolate mofetil with cyclosporine microemulsion or tacrolimus following liver transplantation. Clin Transplant 2004; 18: 463-472.
188. Gaglio PJ, Malireddy S, Levitt BS, et al. Increased risk of cholestatic hepatitis C in recipients of grafts from living versus cadaveric liver donors. Liver Transpl 2003; 9: 1028-1035.
189. Garcia-Retortillo M, Forns X, Llovet JM, et al. Hepatitis C recurrence is more severe after living donor compared to cadaveric liver transplantation. Hepatology 2004; 40: 699-707.
190. Ghobrial RM, Steadman R, Gornbein J, et al. A 10-year experience of liver transplantation for hepatitis C: Analysis of factors determining outcome in over 500 patients. Ann Surg 2001; 234: 384-393; discussion 393-384.
191. Guo L, Orrego M, Rodriguez-Luna H, et al. Living donor liver transplantation for hepatitis C-related cirrhosis: No difference in histological recurrence when compared to deceased donor liver transplantation recipients. Liver Transpl 2006; 12: 560-565.
192. Jain A, Kashyap R, Demetris AJ, Eghstesad B, Pokharna R, Fung JJ,. A prospective randomized trial of mycophenolate mofetil in liver transplant recipients with hepatitis C. Liver Transpl 2002; 8: 40-46.
193. Levy G, Villamil F, Samuel D, et al. Results of lis2t, a multicenter, randomized study comparing cyclosporine microemulsion with C2 monitoring and tacrolimus with C0 monitoring in de novo liver transplantation. Transplantation 2004; 77: 1632-1638.
194. Llado L, Xiol X, Figueras J, et al. Immunosuppression without steroids in liver transplantation is safe and reduces infection and metabolic complications: Results from a prospective multicenter randomized study. J Hepatol 2006; 44: 710-716.
195. Martin P, Busuttil RW, Goldstein RM, et al. Impact of tacrolimus versus cyclosporine in hepatitis C virus-infected liver transplant recipients on recurrent hepatitis: A prospective, randomized trial. Liver Transpl 2004; 10: 1258-1262.
196. Olthoff KM, Merion RM, Ghobrial RM, et al. Outcomes of 385 adult-to-adult living donor liver transplant recipients: A report from the A2ALL Consortium. Ann Surg 2005; 242: 314-323, discussion 323-315.
197. Russo MW, Galanko J, Beavers K, Fried MW, Shrestha R,. Patient and graft survival in hepatitis C recipients after adult living donor liver transplantation in the United States. Liver Transpl 2004; 10: 340-346.
198. Schiano TD, Gutierrez JA, Walewski JL, et al. Accelerated hepatitis C virus kinetics but similar survival rates in recipients of liver grafts from living versus deceased donors. Hepatology 2005; 42: 1420-1428.
199. Shiffman ML, Stravitz RT, Contos MJ, et al. Histologic recurrence of chronic hepatitis C virus in patients after living donor and deceased donor liver transplantation. Liver Transpl 2004; 10: 1248-1255.
200. Takada Y, Haga H, Ito T, et al. Clinical outcomes of living donor liver transplantation for hepatitis C virus (HCV)-positive patients. Transplantation 2006; 81: 350-354.
201. Terrault NA, Shiffman ML, Lok AS, et al. Outcomes in hepatitis C virus-infected recipients of living donor vs. deceased donor liver transplantation. Liver Transpl 2007; 13: 122-129.
202. Wiesner R, Rabkin J, Klintmalm G, et al. A randomized double-blind comparative study of mycophenolate mofetil and azathioprine in combination with cyclosporine and corticosteroids in primary liver transplant recipients. Liver Transpl 2001; 7: 442-450.
203. Zekry A, Gleeson M, Guney S, McCaughan GW,. A prospective cross-over study comparing the effect of mycophenolate versus azathioprine on allograft function and viral load in liver transplant recipients with recurrent chronic HCV infection. Liver Transpl 2004; 10: 52-57.
204. Zervos XA, Weppler D, Fragulidis GP, et al. Comparison of tacrolimus with microemulsion cyclosporine as primary immunosuppression in hepatitis C patients after liver transplantation. Transplantation 1998; 65: 1044-1046.
205. McKenna GJ, Trotter JF, Klintmalm E, et al. Limiting hepatitis C virus progression in liver transplant recipients using sirolimus-based immunosuppression. Am J Transplant 2011; 11: 2379-2387.
206. Watt K, Dierkhising R, Heimbach J, Charlton M,. Impact of sirolimus and tacrolimus on mortality & graft loss in liver transplant recipients with and without HCV-an analysis of the SRTR database. Liver Transpl 2012.
207. Wilson S, Mangus RS, Tector AJ, et al. Use of infected liver donors in liver transplantation: A case-control study. Gastroenterology 2007; 132: A728.
208. Northup PG, Argo CK, Nguyen DT, et al. Liver allografts from hepatitis C positive donors can offer good outcomes in hepatitis C positive recipients: A US National Transplant Registry analysis. Transpl Int; 23: 1038-1044.
209. Lai JC, O'Leary JG, Trotter JF, et al. Risk of advanced fibrosis with grafts from hepatitis C antibody-positive donors: A multicenter cohort study. Liver Transpl; 18: 532-538.
210. Terrault NA, Roland ME, Schiano T, et al. Outcomes of liver transplant recipients with hepatitis C and human immunodeficiency virus coinfection. Liver Transpl; 18: 716-726.
211. Watt K, Veldt B, Charlton M,. A practical guide to the management of HCV infection following liver transplantation. Am J Transplant 2009; 9: 1707-1713.
212. Neumann UP, Berg T, Bahra M, et al. Fibrosis progression after liver transplantation in patients with recurrent hepatitis C. J Hepatol 2004; 41(5): 830-836.
213. Skripenova S, Trainer TD, Krawitt EL, Blaszyk H,. Variability of grade and stage in simultaneous paired liver biopsies in patients with hepatitis C. J Clin Pathol 2007; 60: 321-324.
214. Wiesner RH, Sorrell M, Villamil F,. Report of the first International Liver Transplantation Society expert panel consensus conference on liver transplantation and hepatitis C. Liver Transpl 2003; 9: S1-9.
215. Blasco A, Forns X, Carrion JA, et al. Hepatic venous pressure gradient identifies patients at risk of severe hepatitis C recurrence after liver transplantation. Hepatology 2006; 43: 492-499.
216. Samonakis DN, Cholongitas E, Thalheimer U, et al. Hepatic venous pressure gradient to assess fibrosis and its progression after liver transplantation for HCV cirrhosis. Liver Transpl 2007; 13: 1305-1311.
217. Carrion JA, Navasa M, Garcia-Retortillo M, et al. Efficacy of antiviral therapy on hepatitis C recurrence after liver transplantation: A randomized controlled study. Gastroenterology 2007; 132: 1746-1756.
218. Kalambokis G, Manousou P, Samonakis D, et al. Clinical outcome of HCV-related graft cirrhosis and prognostic value of hepatic venous pressure gradient. Transpl Int 2008.
219. Carrion JA, Navasa M, Bosch J, Bruguera M, Gilabert R, Forns X,. Transient elastography for diagnosis of advanced fibrosis and portal hypertension in patients with hepatitis C recurrence after liver transplantation. Liver Transpl 2006; 12: 1791-1798.
220. Benlloch S, Berenguer M, Prieto M, Rayon JM, Aguilera V, Berenguer J,. Prediction of fibrosis in HCV-infected liver transplant recipients with a simple noninvasive index. Liver Transpl 2005; 11: 456-462.
221. Piscaglia F, Cucchetti A, Benlloch S, et al. Prediction of significant fibrosis in hepatitis C virus infected liver transplant recipients by artificial neural network analysis of clinical factors. Eur J Gastroenterol Hepatol 2006; 18: 1255-1261.
222. Crippin JS, McCashland T, Terrault N, Sheiner P, Charlton MR,. A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation. Liver Transpl 2002; 8: 350-355.
223. Everson GT, Trotter J, Forman L, et al. Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy. Hepatology 2005; 42: 255-262.
224. Forns X, Garcia-Retortillo M, Serrano T, et al. Antiviral therapy of patients with decompensated cirrhosis to prevent recurrence of hepatitis C after liver transplantation. J Hepatol 2003; 39: 389-396.
225. Jacobson I, McHutchison J, Dusheiko G,. Telaprevir in combination with peginterferon and ribavirin in genotype 1 HCV treatment-naive patients: Final results of phase 3 ADVANCE study. Hepatology 2010; 52: 427A.
226. Poordad F, McCone J, Jr., Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1195-1206.
227. Kuo A, Tan V, Lan B, et al. Long-term histological effects of preemptive antiviral therapy in liver transplant recipients with hepatitis C virus infection. Liver Transpl 2008; 14: 1491-1497.
228. Chalasani N, Manzarbeitia C, Ferenci P, et al. Peginterferon alfa-2a for hepatitis C after liver transplantation: Two randomized, controlled trials. Hepatology 2005; 41: 289-298.
229. Sheiner PA, Boros P, Klion FM, et al. The efficacy of prophylactic interferon alfa-2b in preventing recurrent hepatitis C after liver transplantation. Hepatology 1998; 28: 831-838.
230. Shergill AK, Khalili M, Straley S, et al. Applicability, tolerability and efficacy of preemptive antiviral therapy in hepatitis C-infected patients undergoing liver transplantation. Am J Transplant 2005; 5: 118-124.
231. Angelico M, Petrolati A, Lionetti R, et al. A randomized study on Peg-interferon alfa-2a with or without ribavirin in liver transplant recipients with recurrent hepatitis C. J Hepatol 2007; 46: 1009-1017.
232. Babatin M, Schindel L, Burak KW,. Pegylated-interferon alpha 2b and ribavirin for recurrent hepatitis C after liver transplantation: From a Canadian experience to recommendations for therapy. Can J Gastroenterol 2005; 19: 359-365.
233. Beckebaum S, Cicinnati VR, Zhang X, et al. Combination therapy with peginterferon alpha-2B and ribavirin in liver transplant recipients with recurrent HCV infection: Preliminary results of an open prospective study. Transplant Proc 2004; 36: 1489-1491.
234. Berenguer M, Palau A, Fernandez A, et al. Efficacy, predictors of response, and potential risks associated with antiviral therapy in liver transplant recipients with recurrent hepatitis C. Liver Transpl 2006; 12: 1067-1076.
235. Castells L, Vargas V, Allende H, et al. Combined treatment with pegylated interferon (alpha-2b) and ribavirin in the acute phase of hepatitis C virus recurrence after liver transplantation. J Hepatol 2005; 43: 53-59.
236. Dumortier J, Scoazec JY, Chevallier P, Boillot O,. Treatment of recurrent hepatitis C after liver transplantation: A pilot study of peginterferon alfa-2b and ribavirin combination. J Hepatol 2004; 40: 669-674.
237. Gane EJ, Lo SK, Riordan SM, et al. A randomized study comparing ribavirin and interferon alfa monotherapy for hepatitis C recurrence after liver transplantation. Hepatology 1998; 27: 1403-1407.
238. Moreno Planas JM, Rubio Gonzalez E, Boullosa Grana E, et al. Peginterferon and ribavirin in patients with HCV cirrhosis after liver transplantation. Transplant Proc 2005; 37: 2207-2208.
239. Mukherjee S, Rogge J, Weaver L, Schafer DF,. Pilot study of pegylated interferon alfa-2b and ribavirin for recurrent hepatitis C after liver transplantation. Transplant Proc 2003; 35: 3042-3044.
240. Neff GW, Montalbano M, O'Brien CB, et al. Treatment of established recurrent hepatitis C in liver-transplant recipients with pegylated interferon-alfa-2b and ribavirin therapy. Transplantation 2004; 78: 1303-1307.
241. Rodriguez-Luna H, Khatib A, Sharma P, et al. Treatment of recurrent hepatitis C infection after liver transplantation with combination of pegylated interferon alpha2b and ribavirin: An open-label series. Transplantation 2004; 77: 190-194.
242. Ross AS, Bhan AK, Pascual M, Thiim M, Benedict Cosimi A, Chung RT,. Pegylated interferon alpha-2b plus ribavirin in the treatment of post-liver transplant recurrent hepatitis C. Clin Transplant 2004; 18: 166-173.
243. Sharma P, Marrero JA, Fontana RJ, et al. Sustained virologic response to therapy of recurrent hepatitis C after liver transplantation is related to early virologic response and dose adherence. Liver Transpl 2007; 13: 1100-1108.
244. Toniutto P, Fabris C, Fumo E, et al. Pegylated versus standard interferon-alpha in antiviral regimens for post-transplant recurrent hepatitis C: Comparison of tolerability and efficacy. J Gastroenterol Hepatol 2005; 20: 577-582.
245. Wang CS, Ko HH, Yoshida EM, Marra CA, Richardson K,. Interferon-based combination anti-viral therapy for hepatitis C virus after liver transplantation: A review and quantitative analysis. Am J Transplant 2006; 6: 1586-1599.
246. Feray C, Samuel D, Gigou M, et al. An open trial of interferon alfa recombinant for hepatitis C after liver transplantation: Antiviral effects and risk of rejection. Hepatology 1995; 22 (Pt 1): 1084-1089.
247. Levitsky J, Fiel MI, Norvell JP, et al. Risk for immune-mediated graft dysfunction in liver transplant recipients with recurrent HCV infection treated with pegylated interferon. Gastroenterology 2012; 142: 1132-1139 e1131.
248. Garg V, van Heeswijk R, Lee JE, Alves K, Nadkarni P, Luo X,. Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus. Hepatology 2011; 54: 20-27.
249. McLarnon A,. Liver transplantation: Boceprevir increases levels of ciclosporin and tacrolimus. Nat Rev Gastroenterol Hepatol 2012.
250. Davis GL, Nelson DR, Terrault N, et al. A randomized, open-label study to evaluate the safety and pharmacokinetics of human hepatitis C immune globulin (Civacir) in liver transplant recipients. Liver Transpl 2005; 11: 941-949.
251. Vandelli C, Renzo F, Romano L, et al. Lack of evidence of sexual transmission of hepatitis C among monogamous couples: Results of a 10-year prospective follow-up study. Am J Gastroenterol 2004; 99: 855-859.
252. Sanchez-Quijano A, Rey C, Aguado I, et al. Hepatitis C virus infection in sexually promiscuous groups. Eur J Clin Microbiol Infect Dis 1990; 9: 610-612.
253. Tahan V, Karaca C, Yildirim B, et al. Sexual transmission of HCV between spouses. Am J Gastroenterol 2005; 100: 821-824.
254. Finelli L, Miller JT, Tokars JI, Alter MJ, Arduino MJ,. National surveillance of dialysis-associated diseases in the United States, 2002. Semin Dialysis 2005; 18: 52-61.
255. Fissell RB, Bragg-Gresham JL, Woods JD, et al. Patterns of hepatitis C prevalence and seroconversion in hemodialysis units from three continents: The DOPPS. Kidney Int 2004; 65: 2335-2342.
256. Gasink LB, Blumberg EA, Localio AR, Desai SS, Israni AK, Lautenbach E,. Hepatitis C virus seropositivity in organ donors and survival in heart transplant recipients. JAMA 2006; 296: 1843-1850.
257. Cotler SJ, Jensen DM, Kesten S,. Hepatitis C virus infection and lung transplantation: A survey of practices. J Heart Lung Transplant 1999; 18: 456-459.
258. Zylberberg H, Nalpas B, Carnot F, et al. Severe evolution of chronic hepatitis C in renal transplantation: A case control study. Nephrol Dial Transplant 2002; 17: 129-133.
259. Roth D, Gaynor JJ, Reddy KR, et al. Effect of kidney transplantation on outcomes among patients with hepatitis C. J Am Soc Nephrol; 22: 1152-1160.
260. Alric L, Di-Martino V, Selves J, et al. Long-term impact of renal transplantation on liver fibrosis during hepatitis C virus infection. Gastroenterology 2002; 123: 1494-1499.
261. Izopet J, Rostaing L, Sandres K, et al. Longitudinal analysis of hepatitis C virus replication and liver fibrosis progression in renal transplant recipients. J Infect Dis 2000; 181: 852-858.
262. Kokado Y, Takahara S, Ichimaru N, et al. Clinical outcome of HCV infection after renal transplantation. Transplant Proc 2000; 32: 1940-1943.
263. Romero E, Galindo P, Bravo JA, et al. Hepatitis C virus infection after renal transplantation. Transplant Proc 2008; 40: 2933-2935.
264. Gonzalez-Roncero F, Gentil MA, Valdivia MA, et al. Outcome of kidney transplant in chronic hepatitis C virus patients: Effect of pretransplantation interferon-alpha2b monotherapy. Transplant Proc 2003; 35: 1745-1747.
265. Lopez-Medrano F, Fernandez-Ruiz M, Morales JM, et al. Impact of hepatitis C virus infection on the risk of infectious complications after kidney transplantation: Data from the RESITRA/REIPI cohort. Transplantation; 92: 543-549.
266. Kamar N, Rostaing L, Selves J, et al. Natural history of hepatitis C virus-related liver fibrosis after renal transplantation. Am J Transplant 2005; 5: 1704-1712.
267. Fabrizi F, Martin P, Dixit V, Bunnapradist S, Dulai G,. Meta-analysis: Effect of hepatitis C virus infection on mortality in dialysis. Aliment Pharmacol Ther 2004; 20: 1271-1277.
268. Goodkin DA, Bragg-Gresham JL, Koenig KG, et al. Association of comorbid conditions and mortality in hemodialysis patients in Europe, Japan, and the United States: The Dialysis Outcomes and Practice Patterns Study (DOPPS). J Am Soc Nephrol 2003; 14: 3270-3277.
269. Lunel F, Cadranel JF, Rosenheim M, et al. Hepatitis virus infections in heart transplant recipients: Epidemiology, natural history, characteristics, and impact on survival. Gastroenterology 2000; 119: 1064-1074.
270. Wells JT, Lucey MR, Said A,. Hepatitis C in transplant recipients of solid organs, other than liver. Clin Liver Dis 2006; 10: 901-917.
271. Miguel M, Sampaio MS, Kuo HT, Poommipanit N, Martin P, Bunnapradist S,. Influence of preexisting hepatitis C virus antibody positivity in simultaneous pancreas-kidney transplant recipients. Transplantation 2010; 90: 61-67.
272. Fong TL, Cho YW, Hou L, Hutchinson IV, Barbers RG, Herrington CS,. Outcomes after lung transplantation and practices of lung transplant programs in the United States regarding hepatitis C seropositive recipients. Transplantation; 91: 1293-1296.
273. Doucette KE, Weinkauf J, Jackson K, Lein D,. Survival following lung transplantation is not impacted by hepatitis C infection. Am J Transplant 2012; 12 (s3): 472.
274. Morales JM, Campistol JM,. Transplantation in the patient with hepatitis C. J Am Soc Nephrol 2000; 11: 1343-1353.
275. Doucette KE, Weinkauf J, Sumner S, Ens K, Lien D,. Treatment of hepatitis C in potential lung transplant candidates. Transplantation 2007; 83: 1652-1655.
276. Garcia Agudo R, Aoufi Rabih S, Perez Roldan F, et al. Hepatic venous pressure gradient and transjugular liver biopsy to assess patients with kidney failure and chronic liver disease. Nefrologia 2011; 31: 490-492.
277. Rostaing L, Modesto A, Baron E, Cisterne JM, Chabannier MH, Durand D,. Acute renal failure in kidney transplant patients treated with interferon alpha 2b for chronic hepatitis C. Nephron 1996; 74: 512-516.
278. Weclawiack H, Kamar N, Mehrenberger M, et al. Alpha-interferon therapy for chronic hepatitis C may induce acute allograft rejection in kidney transplant patients with failed allografts. Nephrol Dial Transplant 2008; 23: 1043-1047.
279. Chan SE, Schwartz JM, Rosen HR,. Treatment of hepatitis C in solid organ transplantation. Drugs 2004; 64: 489-498.
280. Zeman M, Campbell P, Bain VG,. Hepatitis C eradication and improvement of cryoglobulinemia-associated rash and membranoproliferative glomerulonephritis with interferon and ribavirin after kidney transplantation. Can J Gastroenterol 2006; 20: 427-431.
281. Tang S, Cheng IK, Leung VK, et al. Successful treatment of hepatitis C after kidney transplantation with combined interferon alpha-2b and ribavirin. J Hepatol 2003; 39: 875-878.
282. KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease. Kidney Int Suppl 2008: S1-99.
283. KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease. Kidney disease: Improving global outcomes (KDIGO). Kidney Int Suppl 2008 Apr; (109): S1-99.
284. Fabrizi F, Dixit V, Martin P, Messa P,. Combined antiviral therapy of hepatitis C virus in dialysis patients: Meta-analysis of clinical trials. J Viral Hepat; 18: e263-269.
285. Fabrizi F, Dixit V, Messa P, Martin P,. Pegylated interferon monotherapy of chronic hepatitis C in dialysis patients: Meta-analysis of clinical trials. J Med Virol; 82: 768-775.
286. Bruchfeld A, Lindahl K, Reichard O, Carlsson T, Schvarcz R,. Pegylated interferon and ribavirin treatment for hepatitis C in haemodialysis patients. J Viral Hepat 2006; 13: 316-321.
287. Bruchfeld A, Stahle L, Andersson J, Schvarcz R,. Ribavirin treatment in dialysis patients with chronic hepatitis C virus infection-a pilot study. J Viral Hepat 2001; 8: 287-292.
288. Carriero D, Fabrizi F, Uriel AJ, Park J, Martin P, Dieterich DT,. Treatment of dialysis patients with chronic hepatitis C using pegylated interferon and low-dose ribavirin. Int J Artif Organs 2008; 31: 295-302.
289. Mousa DH, Abdalla AH, Al-Shoail G, Al-Sulaiman MH, Al-Hawas FA, Al-Khader AA,. Alpha-interferon with ribavirin in the treatment of hemodialysis patients with hepatitis C. Transplant Proc 2004; 36: 1831-1834.
290. Tan AC, Brouwer JT, Glue P, et al. Safety of interferon and ribavirin therapy in haemodialysis patients with chronic hepatitis C: Results of a pilot study. Nephrol Dial Transplant 2001; 16: 193-195.
291. van Leusen R, Adang RP, de Vries RA, et al. Pegylated interferon alfa-2a (40 kD) and ribavirin in haemodialysis patients with chronic hepatitis C. Nephrol Dial Transplant 2008; 23: 721-725.
292. Guideline 2: Treatment of HCV in patients with CKD. Kidney Int 2008; 73 (Suppl 109): S20-S45.
293. Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med; 364: 2405-2416.
294. Poordad F, McCone J, Jr., Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med; 364: 1195-1206.
295. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-982.
296. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial. Lancet 2001; 358: 958-965.
297. Steinman TI, Becker BN, Frost AE, et al. Guidelines for the referral and management of patients eligible for solid organ transplantation. Transplantation 2001; 71: 1189-1204.
298. Orens JB, Estenne M, Arcasoy S, et al. International guidelines for the selection of lung transplant candidates: 2006 update-a consensus report from the Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 2006; 25: 745-755.
299. Pereira BJ, Wright TL, Schmid CH, Levey AS,. A controlled study of hepatitis C transmission by organ transplantation. The New England Organ Bank Hepatitis C Study Group. Lancet 1995; 345: 484-487.
300. Delgado J, Munoz de Bustillo E, Ibarrola C, et al. Hepatitis C virus-related fibrosing cholestatic hepatitis after cardiac transplantation: Is azathioprine a contributory factor? J Heart Lung Transplant 1999; 18: 607-610.
301. Delladetsima I, Psichogiou M, Sypsa V, et al. The course of hepatitis C virus infection in pretransplantation anti-hepatitis C virus-negative renal transplant recipients: A retrospective follow-up study. Am J Kidney Dis 2006; 47: 309-316.
302. Maluf DG, Archer KJ, Mas VR,. Kidney grafts from HCV-positive donors: Advantages and disadvantages. Transplant Proc 2010; 42: 2436-2446.
303. Uyar M, Sahin S, Dheir H, Gurkan A,. The influence of hepatitis B and C virus infections on patient and allograft outcomes in kidney transplantation. Transplant Proc 2011; 43: 850-852.
304. Abbott KC, Bucci JR, Matsumoto CS, et al. Hepatitis C and renal transplantation in the era of modern immunosuppression. J Am Soc Nephrol 2003; 14: 2908-2918.
305. Bucci JR, Matsumoto CS, Swanson SJ, et al. Donor hepatitis C seropositivity: Clinical correlates and effect on early graft and patient survival in adult cadaveric kidney transplantation. J Am Soc Nephrol 2002; 13: 2974-2982.
306. Abbott KC, Lentine KL, Bucci JR, Agodoa LY, Peters TG, Schnitzler MA,. The impact of transplantation with deceased donor hepatitis C-positive kidneys on survival in wait-listed long-term dialysis patients. Am J Transplant 2004; 4: 2032-2037.
307. Kucirka LM, Singer AL, Ros RL, Montgomery RA, Dagher NN, Segev DL,. Underutilization of hepatitis C-positive kidneys for hepatitis C-positive recipients. Am J Transplant; 10: 1238-1246.
308. Pascarella S, Negro F,. Hepatitis D virus: An update. Liver Int 2011; 31: 7-21.
309. Farci P,. Delta hepatitis: An update. J Hepatol 2003; 39 (Suppl 1): S212-219.
310. Mederacke I, Bremer B, Heidrich B, et al. Establishment of a novel quantitative hepatitis D virus (HDV) RNA assay using the Cobas TaqMan platform to study HDV RNA kinetics. J Clin Microbiol 2010; 48: 2022-2029.
311. Borghesio E, Rosina F, Smedile A, et al. Serum immunoglobulin M antibody to hepatitis D as a surrogate marker of hepatitis D in interferon-treated patients and in patients who underwent liver transplantation. Hepatology 1998; 27: 873-876.
312. Ottobrelli A, Marzano A, Smedile A, et al. Patterns of hepatitis delta virus reinfection and disease in liver transplantation. Gastroenterology 1991; 101: 1649-1655.
313. Samuel D, Zignego AL, Reynes M, et al. Long-term clinical and virological outcome after liver transplantation for cirrhosis caused by chronic delta hepatitis. Hepatology 1995; 21: 333-339.
314. Lerut JP, Donataccio M, Ciccarelli O, et al. Liver transplantation and HBsAg-positive postnecrotic cirrhosis: Adequate immunoprophylaxis and delta virus co-infection as the significant determinants of long-term prognosis. J Hepatol 1999; 30: 706-714.
315. Lok AS, Gardiner DF, Lawitz E, et al. Preliminary study of two antiviral agents for hepatitis C genotype 1. N Engl J Med 2012; 366: 216-224.
316. Everson GT, Shiffman ML, Hoefs JC, et al. Quantitative liver function tests improve the prediction of clinical outcomes in chronic hepatitis C: Results from the hepatitis C antiviral long-term treatment against cirrhosis trial. Hepatology 2012; 55: 1019-1029.
317. Sherman KE, Flamm SL, Afdhal NH, et al. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med 2011; 365: 1014-1024.
318. Dienstag JL, Ghany MG, Morgan TR, et al. A prospective study of the rate of progression in compensated, histologically advanced chronic hepatitis C. Hepatology 2011; 54: 396-405.
319. Bzowej N, Nelson DR, Terrault NA, et al. PHOENIX: A randomized controlled trial of peginterferon alfa-2a plus ribavirin as a prophylactic treatment after liver transplantation for hepatitis C virus. Liver Transpl 2011; 17: 528-538.
320. Durlik M, Gaciong Z, Rowinska D, et al. Long-term results of treatment of chronic hepatitis B, C and D with interferon-alpha in renal allograft recipients. Transpl Int 1998; 11 (Suppl 1): S135-139.
321. Bahde R, Holzen JP, Wolters HH, et al. Course of a HBsAg positive liver transplantation in a hepatitis B and D virus coinfected recipient. Ann Hepatol 2011; 10: 355-360.
322. Hopf U, Neuhaus P, Lobeck H, et al. Follow-up of recurrent hepatitis B and delta infection in liver allograft recipients after treatment with recombinant interferon-alpha. J Hepatol 1991; 13: 339-346.
323. Aggarwal R,. Hepatitis E: Historical, contemporary and future perspectives. J Gastroenterol Hepatol 2011; 26 (Suppl 1): 72-82.
324. Lu L, Li C, Hagedorn CH,. Phylogenetic analysis of global hepatitis E virus sequences: Genetic diversity, subtypes and zoonosis. Rev Med Virol 2006; 16: 5-36.
325. Aggarwal R,. Clinical presentation of hepatitis E. Virus Res 2011; 161: 15-22.
326. Haagsma EB, Niesters HG, van den Berg AP, et al. Prevalence of hepatitis E virus infection in liver transplant recipients. Liver Transpl 2009; 15: 1225-1228.
327. Kamar N, Garrouste C, Haagsma EB, et al. Factors associated with chronic hepatitis in patients with hepatitis E virus infection who have received solid organ transplants. Gastroenterology 2011; 140: 1481-1489.
328. Kamar N, Legrand-Abravanel F, Izopet J, Rostaing L,. Hepatitis E virus: What transplant physicians should know. Am J Transplant 2012.
329. Kamar N, Weclawiak H, Guilbeau-Frugier C, et al. Hepatitis E virus and the kidney in solid-organ transplant patients. Transplantation 2012; 93: 617-623.
330. Legrand-Abravanel F, Kamar N, Sandres-Saune K, et al. Hepatitis E virus infection without reactivation in solid-organ transplant recipients, France. Emerg Infect Dis 2011; 17: 30-37.
331. Drobeniuc J, Meng J, Reuter G, et al. Serologic assays specific to immunoglobulin M antibodies against hepatitis E virus: Pangenotypic evaluation of performances. Clin Infect Dis 2010; 51: e24-27.
332. Kamar N, Bendall RP, Peron JM, et al. Hepatitis E virus and neurologic disorders. Emerg Infect Dis 2011; 17: 173-179.
333. Kamar N, Rostaing L, Abravanel F, et al. Pegylated interferon-alpha for treating chronic hepatitis E virus infection after liver transplantation. Clin Infect Dis 2010; 50: e30-33.
334. Shrestha MP, Scott RM, Joshi DM, et al. Safety and efficacy of a recombinant hepatitis E vaccine. N Engl J Med 2007; 356: 895-903.
335. Zhu FC, Zhang J, Zhang XF, et al. Efficacy and safety of a recombinant hepatitis E vaccine in healthy adults: A large-scale, randomised, double-blind placebo-controlled, phase 3 trial. Lancet 2010; 376: 895-902.